PPARG and neoplasm: Additional studies determined that the synergistic inhibition of +SA tumor cell growth resulting from combined low dose treatment of γ-tocotrienol with PPARγ antagonists was associated with a reduction in COX-2, PGDS, PGD2 synthesis, and a corresponding inhibition of cell cycle progression.